Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence NTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGP
Primary information
sequence IDSeq_5799
Peptide sequenceNTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGP
CancerPDF_ID CancerPDF_ID11012, CancerPDF_ID11015, CancerPDF_ID11016,
PMID21805675,21805675,21805675
Protein NameCollagen alpha-1(III) chain,Collagen alpha-1(III) chain,Collagen alpha-1(III) chain
UniprotKB Entry NameCO3A1_HUMAN,CO3A1_HUMAN,CO3A1_HUMAN
FluidUrine,Urine,Urine
M/Z3272.4927,3288.4952,3304.4968
ChargeNA,NA,NA
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF
Peptide Identification techniqueMALDI-TOF-MS,MALDI-TOF-MS,MALDI-TOF-MS
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDR1,1,1
CancerPDF_ID CancerPDF_ID11012, CancerPDF_ID11015, CancerPDF_ID11016,
p-ValueNA,NA,NA
SoftwareNA,NA,NA
Length37,37,37
Cancer TypeMuscle-invasive bladder cancer,Muscle-invasive bladder cancer,Muscle-invasive bladder cancer
DatabaseSwissProt Database,SwissProt Database,SwissProt Database
Modification"Oxidation: 8, 13, 20, 26, 31","Oxidation: 8, 13, 20, 26, 31, 32","Oxidation: 8, 13, 20, 26, 31, 32, 35"
Number of Patients751 bladder cancer and 127 control,751 bladder cancer and 127 control,751 bladder cancer and 127 control
RegulationDifferentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples
ValidationMann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB